Filing Details
Theravance Biopharma, Inc. (NASDAQ:TBPH) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 11, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:TBPH
Theravance Biopharma, Inc. (TBPH) Files Quarterly Report for Q0
Theravance Biopharma, Inc. (NASDAQ:TBPH) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 11, 2026.
At publication ·
What changed
Theravance Biopharma, Inc. (NASDAQ:TBPH) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Theravance Biopharma filed its Q0 2026 quarterly report (Form 10-Q) on August 11, 2026, though the specific revenue figure is not disclosed in this summary.
- The company's stock trades at $16.92 with a market capitalization of $895.4 million as of the filing date.
- The 10-Q filing contains unaudited financial statements and management commentary on business performance, including updated risk factors and emerging trends since the last annual report.
Market Context
Theravance Biopharma, Inc.'s stock currently trades at $16.92 with a market capitalization of $895.4M.
The 10-Q provides Theravance Biopharma, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Theravance Biopharma, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View TBPH Stock Page
Frequently Asked Questions
Where can I read TBPH's SEC filings?
Browse all filings on our TBPH SEC filings page.
What types of SEC filings does Theravance Biopharma, Inc. file?
Public companies like Theravance Biopharma, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
